SCHEMBL20436303

SCHEMBL20436303

CCN(CC)c1cccc(C)c1-c1c(C)cccc1NC(=O)Oc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MGLL Q99685 2/20 0.46
▸ KMT2A Q03164 4/20 0.45
▸ MEN1 O00255 2/20 0.45
▸ GAA P10253 3/20 0.45
▸ BCL9 O00512 1/20 0.44
▸ CTNNB1 P35222 1/20 0.44
▸ MAPT P10636 3/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ ATM Q13315 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ TP53 P04637 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ PTPN7 P35236 1/20 0.39
▸ PTPN12 Q05209 1/20 0.39
▸ PTPN22 Q9Y2R2 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ CYP1A2 P05177 2/20 0.38
▸ CYP3A4 P08684 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20458576 0.92 KMT2A (0.43) MGLLKMT2AMEN1GAABCL9
SCHEMBL20441464 0.79 BCL9 (0.50) MGLLKMT2AMEN1GAABCL9
SCHEMBL10490009 0.77 GAA (0.51) MGLLKMT2AMEN1GAABCL9
SCHEMBL20421656 0.76 ALDH1A1 (0.50) KMT2AGAAMAPTHPGDALDH1A1
SCHEMBL4183001 0.74 MAPT (0.57) MGLLKMT2AMEN1GAABCL9
Hydrochloric Acid SCHEMBL4182996 0.73 MAPT (0.56) MGLLKMT2AMEN1GAABCL9
SCHEMBL8239760 0.73 SMN1; SMN2 (0.56) MGLLGAABCL9CTNNB1SMN1; SMN2
SCHEMBL14704102 0.72 GAA (0.53) MGLLKMT2AMEN1GAABCL9
SCHEMBL132758 0.72 GAA (0.51) MGLLKMT2AMEN1GAABCL9
SCHEMBL30475423 0.71 GAA (0.58) MGLLKMT2AMEN1GAABCL9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11327060-B2 Method for analyzing enantiomer AJINOMOTO CO., INC. (JP) 2022-05-10 — — US disclosed
EP-3358346-B1 ENANTIOMER ANALYSIS METHOD AJINOMOTO KK (JP) 2022-01-19 — — EP disclosed
EP-3358346-A1 ENANTIOMER ANALYSIS METHOD Ajinomoto Co., Inc. (JP) 2018-08-08 — — EP disclosed
US-20180217113-A1 METHOD FOR ANALYZING ENANTIOMER AJINOMOTO CO., INC. (JP) 2018-08-02 — — US disclosed
US-20180217113-A1 METHOD FOR ANALYZING ENANTIOMER AJINOMOTO CO., INC. (JP) 2018-08-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11327060-B2 Method for analyzing enantiomer DCX, INF2, SRD5A2 MGLL 3136/4885KMT2A 1985/4885MEN1 653/4885
US-20180217113-A1 METHOD FOR ANALYZING ENANTIOMER DCX, INF2, SRD5A2 MGLL 3136/4885KMT2A 1985/4885MEN1 653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback